{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:27:41Z","timestamp":1790404061966,"version":"4.1.0"},"reference-count":30,"publisher":"Becaris Publishing Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2019,5]]},"abstract":"\n Aim:<\/jats:bold>\n To describe treatment patterns and outcomes of patients with unresectable stage III and metastatic\/stage IV melanoma.\n Materials & methods:<\/jats:bold>\n An observational retrospective chart review of patients diagnosed with advanced melanoma before 1 November 2015 who initiated a new line of therapy (LOT) from 1 January 2015 to 31 May 2016. \u00a0\n Results:<\/jats:bold>\n Among 487 patients, ipilimumab monotherapy (27.5%) was the most common first line of therapy (1LOT) in 2015, surpassed by nivolumab monotherapy (21.5%) in 2016. 12-month survival was \u226580.1%; proportions were highest forpatients treated with nivolumab + ipilimumab (86.6%). All treatments relatively well tolerated in real-world setting and adverse events were consistent with the previously reported safety profiles.\n Conclusion:<\/jats:bold>\n This study provides important insights into real-world advanced melanoma treatment patterns and demonstrates encouraging treatment safety and patient survival data.\n <\/jats:p>","DOI":"10.2217\/cer-2019-0003","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T09:59:52Z","timestamp":1551779992000},"page":"461-473","source":"Crossref","is-referenced-by-count":21,"title":["Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA"],"prefix":"10.57264","volume":"8","author":[{"given":"Ahmad","family":"Tarhini","sequence":"first","affiliation":[{"name":"Department of Hematology & Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 441062, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Atzinger","sequence":"additional","affiliation":[{"name":"Pharmerit International, Bethesda, MD 208143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Gupte-Singh","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, NJ 086484, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Johnson","sequence":"additional","affiliation":[{"name":"Pharmerit International, Bethesda, MD 208143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Macahilig","sequence":"additional","affiliation":[{"name":"Medical Data Analytics, Parsippany, NJ 07054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumati","family":"Rao","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, NJ 086484, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_5_3_2","unstructured":"National Cancer Institute\n . \n Surveillance Epidemiology and End Results Program. SEER stat fact sheets: melanoma of the skin\n (\n 2018\n ). \n https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html\n ."},{"key":"e_1_3_5_4_2","unstructured":"Bristol-Myers Squibb. Yervoy (ipilimumab) package insert\n (\n 2011\n ). \n https:\/\/packageinserts.bms.com\/pi\/pi_yervoy.pdf\n ."},{"key":"e_1_3_5_5_2","unstructured":"Genentech. Zelboraf (vemurafinib) package insert\n (\n 2011\n ). \n https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202429s012lbl.pdf\n ."},{"key":"e_1_3_5_6_2","unstructured":"Novartis. Tafinlar (dabrafenib) package insert\n (\n 2013\n ). \n https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/202806s002lbl.pdf\n ."},{"key":"e_1_3_5_7_2","unstructured":"Novartis. Mekinist (trametinib) package insert\n (\n 2013\n ). \n https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204114s001lbl.pdf\n ."},{"key":"e_1_3_5_8_2","unstructured":"Merck. Keytruda (pembrolizumab) package insert\n (\n 2014\n ). \n https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\n ."},{"key":"e_1_3_5_9_2","unstructured":"Squib BM. Opdivo (Nivolumab) package insert\n (\n 2014\n ). \n https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf\n ."},{"key":"e_1_3_5_10_2","unstructured":"Genentech. Cotellic (cobimetinib) package insert\n (\n 2015\n ). \n https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206192s000lbl.pdf\n ."},{"issue":"1","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(14)71138-6","article-title":"A new standard of care for metastatic melanoma?","volume":"16","author":"Sharma SP","year":"2015","unstructured":"Sharma SP . A new standard of care for metastatic melanoma? Lancet Oncol. 16 ( 1 ), e8 ( 2015 ).","journal-title":"Lancet Oncol."},{"issue":"1","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J , Chiarion-Sileni V , Gonzalez R Combined nivolumab and ipilimumab or monotherapy in untreated melanoma . N. Engl. J. Med. 373 ( 1 ), 23 \u2013 34 ( 2015 ).","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty KT","year":"2012","unstructured":"Flaherty KT , Infante JR , Daud A Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations . N. Engl. J. Med. 367 ( 18 ), 1694 \u2013 1703 ( 2012 ).","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long GV","year":"2014","unstructured":"Long GV , Stroyakovskiy D , Gogas H Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma . N. Engl. J. Med. 371 ( 20 ), 1877 \u2013 1888 ( 2014 ).","journal-title":"N. Engl. J. Med."},{"issue":"9992","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, Phase III randomised controlled trial","volume":"386","author":"Long GV","year":"2015","unstructured":"Long GV , Stroyakovskiy D , Gogas H Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, Phase III randomised controlled trial . Lancet 386 ( 9992 ), 444 \u2013 451 ( 2015 ).","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C , Karaszewska B , Schachter J Improved overall survival in melanoma with combined dabrafenib and trametinib . N. Engl. J. Med. 372 ( 1 ), 30 \u2013 39 ( 2015 ).","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1200\/JCO.2017.35.15_suppl.9505","article-title":"Five-year overall survival (OS) update from a Phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600\u2013mutant unresectable or metastatic melanoma (MM)","volume":"35","author":"Long GV","year":"2017","unstructured":"Long GV , Eroglu Z , Infante JR Five-year overall survival (OS) update from a Phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600\u2013mutant unresectable or metastatic melanoma (MM) . J. Clin. Oncol. 35 ( 15 Suppl. ), 9505 ( 2017 ).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/cam4.717","article-title":"Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study","volume":"5","author":"Middleton MR","year":"2016","unstructured":"Middleton MR , Dalle S , Claveau J Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study . Cancer Med. 5 ( 7 ), 1436 \u2013 1443 ( 2016 ).","journal-title":"Cancer Med."},{"issue":"1","key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/CMR.0000000000000394","article-title":"Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study","volume":"28","author":"Uprety D","year":"2018","unstructured":"Uprety D , Bista A , Chennamadhavuni A Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study . Melanoma Res. 28 ( 1 ), 56 \u2013 60 ( 2018 ).","journal-title":"Melanoma Res."},{"issue":"2","key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/CJI.0000000000000204","article-title":"Pembrolizumab utilization and outcomes for advanced melanoma in US community oncology practices","volume":"41","author":"Cowey CL","year":"2018","unstructured":"Cowey CL , Liu FX , Black-Shinn J Pembrolizumab utilization and outcomes for advanced melanoma in US community oncology practices . J. Immunother. 41 ( 2 ), 86 \u2013 95 ( 2018 ).","journal-title":"J. Immunother."},{"issue":"4","key":"e_1_3_5_21_2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.6004\/jnccn.2016.0051","article-title":"Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Coit DG","year":"2016","unstructured":"Coit DG , Thompson JA , Algazi A Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology . J. Natl Compr. Canc. Netw. 14 ( 4 ), 450 \u2013 473 ( 2016 ).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"e_1_3_5_22_2","unstructured":"National Comprehensive Cancer Network\n . \n NCCN Guidelines \u2013 melanoma. NCCN Guidelines\n Version 2.2018\n (\n 2018\n )."},{"issue":"6","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/09546634.2016.1277176","article-title":"Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States","volume":"28","author":"Ma Q","year":"2017","unstructured":"Ma Q , Chen YJ , Hines DM Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States . J. Dermatolog. Treat. 28 ( 6 ), 549 \u2013 553 ( 2017 ).","journal-title":"J. Dermatolog. Treat."},{"issue":"8","key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1185\/03007995.2015.1062356","article-title":"Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting","volume":"31","author":"Toy EL","year":"2015","unstructured":"Toy EL , Vekeman F , Lewis MC , Oglesby AK , Duh MS . Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting . Curr. Med. Res. Opin. 31 ( 8 ), 1561 \u2013 1572 ( 2015 ).","journal-title":"Curr. Med. Res. Opin."},{"issue":"8","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","unstructured":"Hodi FS , O'Day SJ , Mcdermott DF Improved survival with ipilimumab in patients with metastatic melanoma . N. Engl. J. Med. 363 ( 8 ), 711 \u2013 723 ( 2010 ).","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow MA","year":"2015","unstructured":"Postow MA , Chesney J , Pavlick AC Nivolumab and ipilimumab versus ipilimumab in untreated melanoma . N. Engl. J. Med. 372 ( 21 ), 2006 \u2013 2017 ( 2015 ).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C , Long GV , Brady B Nivolumab in previously untreated melanoma without BRAF mutation . N. Engl. J. Med. 372 ( 4 ), 320 \u2013 330 ( 2015 ).","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C , Schachter J , Long GV Pembrolizumab versus Ipilimumab in advanced melanoma . N. Engl. J. Med. 372 ( 26 ), 2521 \u2013 2532 ( 2015 ).","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-16-0664","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma","volume":"23","author":"Barone A","year":"2017","unstructured":"Barone A , Hazarika M , Theoret MR FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma . Clin. Cancer Res. 23 ( 19 ), 5661 \u2013 5665 ( 2017 ).","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, Phase II trial","volume":"17","author":"Hodi FS","year":"2016","unstructured":"Hodi FS , Chesney J , Pavlick AC Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, Phase II trial . Lancet Oncol. 17 ( 11 ), 1558 \u2013 1568 ( 2016 ).","journal-title":"Lancet Oncol."},{"issue":"8","key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, Phase II trial","volume":"16","author":"Ribas A","year":"2015","unstructured":"Ribas A , Puzanov I , Dummer R Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, Phase II trial . Lancet Oncol. 16 ( 8 ), 908 \u2013 918 ( 2015 ).","journal-title":"Lancet Oncol."},{"issue":"4","key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase III trial","volume":"16","author":"Weber JS","year":"2015","unstructured":"Weber JS , D'Angelo SP , Minor D Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase III trial . Lancet Oncol. 16 ( 4 ), 375 \u2013 384 ( 2015 ).","journal-title":"Lancet Oncol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2019-0003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:39:32Z","timestamp":1679229572000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2019-0003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.2217\/cer-2019-0003"],"URL":"https:\/\/doi.org\/10.2217\/cer-2019-0003","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}